Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease

Open access

Abstract

Invasive fungal infections are a leading cause of mortality among immunocompromised individuals. Treatment is notoriously difficult with the limited armamentarium of antifungal drugs, whose efficacy is compromised by host toxicity, a limited activity spectrum, or the emergence of drug resistance. We previously established that the molecular chaperone Hsp90 enables the emergence and maintenance of fungal drug resistance. For the most prevalent fungal pathogen of humans, Candida albicans , Hsp90 mediates resistance to azoles, which inhibit ergosterol biosynthesis and are the most widely deployed antifungals in the clinic. For the emerging opportunistic pathogen Aspergillus terreus , Hsp90 is required for basal resistance to echinocandins, which inhibit β(1, 3)-glucan synthesis and are the only new class of antifungals to reach the clinic in decades. Here, we explore the therapeutic potential of Hsp90 inhibitors in fungal disease using a tractable host-model system, larvae of the greater wax moth Galleria mellonella , and a murine model of disseminated disease. Combination therapy with Hsp90 inhibitors that are well tolerated in humans and an azole rescued larvae from lethal C. albicans infections. Combination therapy with an Hsp90 inhibitor and an echinocandin rescued larvae from infections with the most lethal mold, Aspergillus fumigatus . In a murine model of disseminated candidiasis, genetic compromise of C. albicans HSP90 expression enhanced the therapeutic efficacy of an azole. Thus, harnessing Hsp90 provides a much-needed strategy for improving the treatment of fungal disease because it enhances the efficacy of existing antifungals, blocks the emergence of drug resistance, and exerts broad-spectrum activity against diverse fungal pathogens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0813394106

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. 10.1111/j.1574-695X.2002.tb00617.x · doi:10.1111/j.1574-695x.2002.tb00617.x · Paper page

Cited by

See all 416

Metadata

Authors
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., & Lindquist, S.
Affiliations
  • University of Toronto (CA)
  • Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada;
  • Boston Children's Hospital (US)
  • Duke Medical Center (US)
  • Harvard University (US)
  • Howard Hughes Medical Institute (US)
Venue
Proceedings of the National Academy of Sciences
Published
2009-02-24
Volume
106
Issue
8
Pages
2818-2823
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1995380559
Cited by
413
References
47
Citations by year
2026: 13 · 2025: 19 · 2024: 27 · 2023: 19 · 2022: 25 · 2021: 23 · 2020: 25 · 2019: 20 · 2018: 26 · 2017: 16 · 2016: 28 · 2015: 27 · 2014: 22 · 2013: 28 · 2012: 33
FWCI
21.98
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Howard Hughes Medical Institute
  • Burroughs Wellcome Fund
  • Damon Runyon Cancer Research Foundation
  • University of Toronto
  • National Institutes of Health
  • Canadian Institutes of Health Research (MOP-86452)
  • National Institute of Allergy and Infectious Diseases (AI 73896, R56AI028388, AI28388, R01AI073896, R21AI063449, R01AI028388, K08AI065837)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
Hsp90 inhibitors, invasive fungal infections, Candida albicans, Aspergillus terreus, Aspergillus fumigatus, azole resistance, echinocandin resistance, antifungal resistance, combination antifungal therapy, Galleria mellonella larvae, systemic candidiasis, molecular chaperones, ergosterol biosynthesis
MeSH terms
Animals, Antifungal Agents, Fungi, Humans, Male, Microbial Sensitivity Tests, Mycoses, Fluconazole, HSP90 Heat-Shock Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. https://app.cochat.ai/papers/10.1073/pnas.0813394106
The paper
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., & Lindquist, S. (2009). Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0813394106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.